Senseonics Holdings, Inc. Common Stock’s (SENS) “Buy” Rating Reiterated at TD Cowen

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)‘s stock had its “buy” rating reissued by equities researchers at TD Cowen in a report released on Tuesday, Benzinga reports. They presently have a $15.00 price objective on the stock. TD Cowen‘s price objective would suggest a potential upside of 64.73% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Barclays initiated coverage on Senseonics Holdings, Inc. Common Stock in a research report on Wednesday, October 7th. They set an “equal weight” rating and a $10.00 price target for the company. Mizuho reduced their price objective on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Weiss Ratings lowered Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 22nd. Finally, Wall Street Zen raised Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Senseonics Holdings, Inc. Common Stock Price Performance

Senseonics Holdings, Inc. Common Stock stock traded up $0.78 on Tuesday, reaching $9.11. The company’s stock had a trading volume of 283,666 shares, compared to its average volume of 662,749. The business’s fifty day moving average price is $9.15 and its 200 day moving average price is $7.17. Senseonics Holdings, Inc. Common Stock has a twelve month low of $4.79 and a twelve month high of $10.64.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The business had revenue of $14.48 million for the quarter. Equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.31 earnings per share for the current fiscal year.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In related news, Director Douglas Roeder acquired 13,953 shares of the stock in a transaction dated Wednesday, August 19th. The stock was purchased at an average cost of $8.98 per share, with a total value of $125,297.94. Following the completion of the purchase, the director directly owned 171,191 shares in the company, valued at $1,537,295.18. This trade represents a 8.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SENS. Integrated Wealth Concepts LLC purchased a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter worth $36,000. Readystate Asset Management LP purchased a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter worth $574,000. Penn Capital Management Company LLC purchased a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter worth $535,000. Stonepine Capital Management LLC purchased a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter worth $276,502. Finally, Jefferies Financial Group Inc. purchased a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter worth $102,000. 12.36% of the stock is owned by institutional investors.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application.

The company’s primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.